Immunocore Reports
Second Quarter
2023 Financial Results
and Provides Business Update
KIMMTRAK net revenues of £45.5 million ($57.8
million) in 2Q 2023; new launches in Italy, Austria, Finland, and
Israel with additional European launches expected by year-end
New Phase 3 Trial for IMC-F106C (PRAME-A02) in
first-line cutaneous melanoma (PRISM-MEL301); expect first patient
randomized by 1Q 2024
Enrolling patients in monotherapy and combination
arms of IMC-F106C in Phase 1/2 trial, including expansions in
melanoma, NSCLC, endometrial, and ovarian cancers; data expected in
1H 2024
Cash and cash equivalents increased to £342
million ($435 million) as of June 30, 2023
Conference call today, August 10th at 8:00 AM
EDT, 1:00 PM BST
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 10 August 2023) Immunocore Holdings plc
(Nasdaq: IMCR), a commercial-stage biotechnology company pioneering
the development of a novel class of T cell receptor (TCR)
bispecific immunotherapies designed to treat a broad range of
diseases, including cancer, infectious diseases and autoimmune
diseases, today announced its financial results for the second
quarter ended June 30, 2023, and provided a business update.
“I am extremely pleased that KIMMTRAK is reaching more patients,
with approvals now in over 35 countries, leading to another
excellent quarter,” said Bahija Jallal, Chief Executive
Officer of Immunocore. “I am also excited by the progress
of our pipeline, as we announce the first Phase 3 trial with our
PRAME-targeted ImmTAC, in first-line cutaneous melanoma.”
“IMC-F106C, the first PRAME-targeted bispecific therapy, has
demonstrated durable clinical activity in melanoma as monotherapy,
leading us to initiate the PRISM-MEL301 Phase 3 trial,” commented
David Berman, EVP Research and Development,
Immunocore. "This melanoma trial, informed by a Type B FDA
meeting and with global expert input, will randomize patients to
IMC-F106C with nivolumab versus global standards of care of
nivolumab with or without relatlimab.”
Second Quarter
2023 Highlights
(including post-period)
KIMMTRAK®
(tebentafusp-tebn)
for metastatic uveal melanoma
(mUM)
KIMMTRAK is approved in over 35 countries globally. Total net
product revenue (or “net sales”) arising from the sale of KIMMTRAK
was £45.5 million (or $57.8 million) in the second quarter of 2023,
of which £32.8 million (or $41.7 million) was in the United States,
£12.2 million (or $15.5 million) in Europe, and £0.5 million (or
$0.6 million) in the rest of the world.
In the United States, growth was driven both by patient
expansion and duration of therapy. The Company estimates market
share increased to approximately 60% of first-line HLA-A*02:01
positive patients with mUM and that duration of therapy in the
real-world setting is tracking towards the greater than nine months
seen in the Phase 2 and Phase 3 clinical trials.
In the first half of the year, the Company launched KIMMTRAK in
Austria and Israel and, most recently, in Italy and Finland. In
France and Germany, KIMMTRAK remains the standard of care for
first-line HLA-A*02:01 positive patients with mUM, with nearly all
patients in Germany being treated in first-line. In early August,
the Company reached a KIMMTRAK pricing reimbursement agreement in
Germany. This price, expected to be published in September 2023, is
slightly improved from the Company’s accounting assumptions. The
Company expects to launch KIMMTRAK in several additional European
countries by the end of 2023.
In July, the Centers for Medicare & Medicaid Services (CMS)
released the 2024 Proposed Rule for the physician fee schedule. The
Proposed Rule names KIMMTRAK as a medicine identified as meeting
the proposed criteria for unique circumstances, whereby it would
have a proposed increased applicable percentage of unused or
discarded product volume subject to refund to CMS, of 45%, and not
10% used for medicines without these unique circumstances. The
Proposed Rule is expected to be finalized during the fourth quarter
of 2023 with an effective date of January 1, 2024.
In the second quarter, the Company presented data
demonstrating:
- association between early
circulating tumor DNA (ctDNA) reduction and longer overall survival
(OS) at the 2023 American Association for Cancer Research (AACR)
Annual Meeting and American Society of Clinical Oncology (ASCO)
2023 meeting. ctDNA clearance was higher in previously untreated
mUM (37%) compared to previously treated mUM (13%). These data
suggest that early ctDNA reduction may be a better predictor of
longer OS than radiographic response.
- final analysis, minimum follow-up of
3 years, from the Phase 2 trial in mUM at AACR 2023. The Company
plans to present updated 3-year overall survival data from the
Phase 3 trial in mUM at a medical conference later this year.
In the second quarter, Sanofi informed Immunocore that they will
not be progressing their evaluation of SAR444245 in combination
with KIMMTRAK. As such, Sanofi elected to terminate the previously
announced clinical trial collaboration, in which Sanofi was
responsible for clinical development. Immunocore is no longer
responsible for supplying KIMMTRAK for this clinical trial and no
other costs are expected.
TEBE-AM - Phase 2
/ 3 trial
with KIMMTRAK in
second-line or later
cutaneous melanoma
Randomization continues in the Phase 2/3
clinical trial of KIMMTRAK in HLA-A*02:01 positive patients with
second-line or later cutaneous melanoma. The trial is randomizing
patients with advanced melanoma who have progressed on an anti-PD1,
received prior ipilimumab and, if applicable, received a BRAF
inhibitor. Patients are being randomized to one of three arms,
including KIMMTRAK as monotherapy or in combination with an
anti-PD1, and a control arm. The Company presented a
trial-in-progress poster at the ASCO 2023 meeting, describing the
design of the trial, which has a dual primary endpoint of OS and
ctDNA reduction. The company expects to complete randomization of
the Phase 2 portion of the study in the second half of 2024.
PRISM-MEL301 –
First PRAME Phase 3 trial with
IMC-F106C in first-line
cutaneous melanoma
The Company, following U.S. Food and Drug Administration (FDA)
Type B interaction, is planning a registrational Phase 3 trial with
IMC-F106C, with the goal of starting by the first quarter of 2024.
The trial will randomize patients with HLA-A*02:01 positive,
first-line cutaneous melanoma to IMC-F106C + nivolumab versus a
control arm of either nivolumab or nivolumab + relatlimab,
depending on country. Based on feedback from the FDA, including
Project Optimus, the study will initially randomize to three arms –
two well-tolerated and clinically active F106C dose regimens (40
mcg and 160 mcg) and the control arm – and will discontinue one of
the F106C dose regimens after an initial review of the first 60
patients randomized to the two experimental arms (90 patients
randomized total). The Company plans to randomize the first patient
in this trial in the first quarter of 2024. The Company estimates
there are over 10,000 newly diagnosed HLA-A*02:01 positive,
advanced cutaneous melanoma patients in the G7 per year.
Phase 1/2 IMC-F106C
targeting PRAME-A02 in multiple solid
tumors
In addition to progressing IMC-F106C into a
registrational trial in advanced melanoma, the Company is
continuing to enroll patients in the Phase 1/2 trial monotherapy
and combination arms across multiple tumor types, including
expansion arms for patients with advanced ovarian, non-small cell
lung, endometrial, and melanoma cancers. Today, the Company is
providing an updated analysis of the original 18 melanoma patients
(initially presented at ESMO in September 2022), which continues to
show promising durability of the clinical activity (range of
duration of partial response from 6 months to 17 months). The
Company expects to report data from the trial in the first half of
2024.
Early oncology
pipeline: IMC-R117C
(PIWIL1), IMC-P115C (PRAME-A02
HLE), IMC-T119C
(PRAME-A24)
The Company is on-track to submit an IND / CTA in the fourth
quarter of 2023 for IMC-R117C, an ImmTAC targeting the PIWIL1
protein for colorectal and other gastrointestinal cancers. The
Company believes this is the first PIWIL1-targeted immunotherapy in
development. The Company continues to work on expanding the PRAME
franchise, with pre-clinical work ongoing for two new PRAME ImmTAC
candidates, IMC-P115C (PRAME-A02 HLE) and IMC-T119C (PRAME-A24) for
solid tumors, with both on-track for IND/CTA submission in
2024.
IMC-M113V and
IMC-I109V:
aiming for functional cure in
HIV and HBV
The Company is enrolling people living with HIV
in the multiple ascending dose (MAD) part of a Phase 1 trial with
IMC-M113V, to identify a safe and tolerable dosing schedule. This
study will also test whether IMC-M113V could lead to reduction in
the viral load and, after stopping all therapies (antiretroviral
therapies and ImmTAV), delay or prevent HIV rebound (known as
functional cure). The MAD part of the trial will enroll up to 28
participants. The Company expects to present a data update in
2024.
In the ongoing Phase 1 trial with IMC-I109V,
enrolling people living with HBV in the single ascending dose
portion, the Company has amended the study to include HBV-positive
hepatocellular carcinoma in the multiple ascending dose portion of
the study.
Financial Results
Total net product revenue arising from the sale of KIMMTRAK was
£45.5 million ($57.8 million) and £87.6 million (£111.3 million) in
the three and six months ended June 30, 2023, respectively, of
which £32.8 million ($41.7 million) and £62.3 million ($79.2
million) was in the United States, £12.2 million ($15.5 million)
and £24.5 million ($31.2 million) was in Europe, and £0.5 million
($0.6 million) and £0.7 million ($0.9 million) was in the rest of
the world. For the three and six months ended June 30, 2022, the
Company recorded total net product and pre-product revenue of £27.7
million and £38.2 million, respectively.
For the three and six months ended June 30, 2023, the Company’s
research and development expenses were £28.8 million ($36.6
million) and £57.2 million ($72.7 million), respectively, as
compared to £20.2 million and £38.7 million for the three and six
months ended June 30, 2022, respectively. For the three and six
months ended June 30, 2023, the selling and administrative expenses
were £33.9 million ($43.1 million) and £67.2 million ($85.4
million), respectively, compared to £18.8 million and £38.9 million
for the three and six months ended June 30, 2022, respectively.
Basic and diluted loss per share for the three and six months
ended June 30, 2023 was £0.29 ($0.37) and £0.64 ($0.81),
respectively, compared to a basic and diluted loss per share of
£0.14 and £0.51 for the three and six months ended June 30, 2022,
respectively.
Cash and cash equivalents were £342.3 million
($435.1 million) as of June 30, 2023, compared to £332.5 million as
of December 31, 2022.
We maintain our books and records in pounds
sterling. For the convenience of the reader, we have translated
pound sterling amounts as of and for the period ended June 30, 2023
into U.S. dollars at a rate of £1.00 to $1.2709.
Audio Webcast
Immunocore will host a conference call today,
August 10, 2023 at 8:00 A.M. EDT/ 1:00 PM BST, to discuss the
second quarter financial results and provide a business update. The
call will also be available via webcast by visiting the Events
& Presentations section on Immunocore’s website. A replay of
this webcast will be available for 30 days.
Conference Call Details:U.S. (toll-free):
877-405-1239International (toll): +1 201-389-0851
Upcoming Investor Conference
- H.C. Wainwright Immune Cell
Engager Virtual Conference
Fireside Chat: Thursday, August 17, 2023, at 1:00 pm ET
###
About PRISM-MEL301 –
Phase 3 trial with IMC-F106C
(PRAMExCD3) in
1L advanced,
cutaneous melanoma
The Phase 3 registrational trial will randomize patients with
previously untreated, HLA-A*02:01 positive, advanced melanoma to
IMC-F106C+nivolumab versus nivolumab or nivolumab + relatlimab,
depending on country. The study will initially randomize to three
arms: two F106C dose regimens (40 mcg and 160 mcg) and control arm,
and will discontinue one of the F106C dose regimens after an
initial review of the first 60 patients randomized to the two
experimental arms (90 patients randomized total). The primary
endpoint of the trial is progression free survival (PFS) by BICR,
with secondary endpoints of overall survival (OS) and overall
response rate (ORR).
About TEBE-AM - Phase 2 / 3
trial with tebentafusp
(gp100xCD3) in
second-line or later cutaneous
melanoma
The trial is randomizing patients with second
line or later cutaneous melanoma who have progressed on an
anti-PD1, received prior ipilimumab and, if applicable, received a
BRAF kinase inhibitor. Patients will be randomized to one of three
arms including tebentafusp, as monotherapy or in combination with
an anti-PD1, and a control arm. The Phase 2 portion of the trial
will include 40 patients per arm.
About ImmTAV molecules
and infectious diseases
ImmTAV (Immune mobilizing monocolonal TCRs Against Virus)
molecules are novel bispecific molecules that, like ImmTAC (Immune
mobilizing monoclonal TCRs Against Cancer) molecules, are designed
to enable the immune system to recognize and eliminate virally
infected cells.
Immunocore is advancing clinical candidates to cure patients
with HIV and HBV. The Company aims to achieve a reduction in viral
reservoirs to enable sustained control of HIV after stopping
antiretroviral therapy (ART), without the risk of virological
relapse or onward transmission. This is known as ‘functional cure’.
For the treatment of HBV, the Company aims to achieve sustained
loss of circulating viral antigens and markers of viral replication
after stopping medication for people living with chronic hepatitis
B.
About Uveal Melanoma
Uveal melanoma is a rare and aggressive form of
melanoma, which affects the eye. Although it is the most common
primary intraocular malignancy in adults, the diagnosis is rare,
and up to 50% of people with uveal melanoma will eventually develop
metastatic disease. Unresectable or metastatic uveal melanoma
typically has a poor prognosis and had no approved treatment until
KIMMTRAK.
About KIMMTRAK®
KIMMTRAK is a novel bispecific protein comprised
of a soluble T cell receptor fused to an anti-CD3 immune-effector
function. KIMMTRAK specifically targets gp100, a lineage antigen
expressed in melanocytes and melanoma. This is the first molecule
developed using Immunocore’s ImmTAC technology platform designed to
redirect and activate T cells to recognize and kill tumor cells.
KIMMTRAK has been approved for the treatment of
HLA-A*02:01-positive adult patients with unresectable or metastatic
uveal melanoma in the United States, European Union, Canada,
Australia, and the United Kingdom.
IMPORTANT SAFETY
INFORMATION
Cytokine Release Syndrome (CRS), which
may be serious or life-threatening, occurred in patients receiving
KIMMTRAK. Monitor for at least 16 hours following first three
infusions and then as clinically indicated. Manifestations
of CRS may include fever, hypotension, hypoxia, chills, nausea,
vomiting, rash, elevated transaminases, fatigue, and headache. CRS
occurred in 89% of patients who received KIMMTRAK with 0.8% being
grade 3 or 4. Ensure immediate access to medications and
resuscitative equipment to manage CRS. Ensure patients are
euvolemic prior to initiating the infusions. Closely monitor
patients for signs or symptoms of CRS following infusions of
KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level
and provide appropriate therapy. Withhold or discontinue KIMMTRAK
depending on persistence and severity of CRS.
Skin Reactions
Skin reactions, including rash, pruritus, and
cutaneous edema occurred in 91% of patients treated with KIMMTRAK.
Monitor patients for skin reactions. If skin reactions occur, treat
with antihistamine and topical or systemic steroids based on
persistence and severity of symptoms. Withhold or permanently
discontinue KIMMTRAK depending on the severity of skin
reactions.
Elevated Liver Enzymes
Elevations in liver enzymes occurred in 65% of
patients treated with KIMMTRAK. Monitor alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and total blood bilirubin
prior to the start of and during treatment with KIMMTRAK. Withhold
KIMMTRAK according to severity.
Embryo-Fetal Toxicity
KIMMTRAK may cause fetal harm. Advise pregnant
patients of potential risk to the fetus and patients of
reproductive potential to use effective contraception during
treatment with KIMMTRAK and 1 week after the last dose.
The most common adverse reactions (≥30%) in
patients who received KIMMTRAK were cytokine release syndrome,
rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain,
edema, hypotension, dry skin, headache, and vomiting. The most
common (≥50%) laboratory abnormalities were decreased lymphocyte
count, increased creatinine, increased glucose, increased AST,
increased ALT, decreased hemoglobin, and decreased phosphate.
For more information, please see full Summary of
Product Characteristics (SmPC) or full U.S. Prescribing Information
(including BOXED WARNING for CRS).
About
KIMMTRAKConnect
Immunocore is committed to
helping patients who need KIMMTRAK obtain access via our
KIMMTRAKConnect program. The program provides services with
dedicated nurse case managers who provide personalized support,
including educational resources, financial assistance, and site of
care coordination. To learn more, visit KIMMTRAKConnect.com or call
844-775-2273.
About Immunocore
Immunocore is a commercial-stage biotechnology
company pioneering the development of a novel class of TCR
bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including five clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been
approved for the treatment of HLA-A*02:01-positive adult patients
with unresectable or metastatic uveal melanoma in the United
States, European Union, Canada, Australia, and the United
Kingdom.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Words such as
“may”, “will”, “believe”, “expect”, “plan”, “anticipate” and
similar expressions (as well as other words or expressions
referencing future events or circumstances) are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release are
forward-looking statements. These statements include, but are not
limited to, the commercial performance of KIMMTRAK including
planned launches in additional countries; the potential benefits
KIMMTRAK will provide for patients; the estimated market share of
KIMMTRAK; the final content of the CMS’ calendar year 2024 rule for
the physician fee schedule and the timing of the release of such
final rule by CMS; the estimated market size and patient population
for the Company’s products and product candidates; the expected
submission of investigational new drug applications or clinical
trial applications; the potential regulatory approval, expected
clinical benefits and availability of Immunocore’s product
candidates; expectations regarding the design, progress, timing,
enrollment, scope, expansion, and results of Immunocore’s existing
and planned clinical trials; and potential growth opportunities and
trends, including in connection with product launches in future
quarters. Any forward-looking statements are based on management’s
current expectations and beliefs of future events and are subject
to a number of risks and uncertainties that could cause actual
events or results to differ materially and adversely from those set
forth in or implied by such forward-looking statements, many of
which are beyond the Company’s control. These risks and
uncertainties include, but are not limited to, the impact of
worsening macroeconomic conditions on the Company’s business,
financial position, strategy and anticipated milestones, including
Immunocore’s ability to conduct ongoing and planned clinical
trials; Immunocore’s ability to obtain a clinical supply of current
or future product candidates or commercial supply of KIMMTRAK or
any future approved products, including as a result of the COVID-19
pandemic, war in Ukraine or global geopolitical tension;
Immunocore’s ability to obtain and maintain regulatory approval of
its product candidates, including KIMMTRAK; Immunocore’s ability
and plans in continuing to establish and expand a commercial
infrastructure and to successfully launch, market and sell KIMMTRAK
and any future approved products; Immunocore’s ability to
successfully expand the approved indications for KIMMTRAK or obtain
marketing approval for KIMMTRAK in additional geographies in the
future; the delay of any current or planned clinical trials,
whether due to patient enrollment delays or otherwise; Immunocore’s
ability to successfully demonstrate the safety and efficacy of its
product candidates and gain approval of its product candidates on a
timely basis, if at all; competition with respect to market
opportunities; unexpected safety or efficacy data observed during
preclinical studies or clinical trials; actions of regulatory
agencies, which may affect the initiation, timing and progress of
clinical trials or future regulatory approval; Immunocore’s need
for and ability to obtain additional funding, on favorable terms or
at all, including as a result of worsening macroeconomic
conditions, including changes inflation and interest rates and
unfavorable general market conditions, and the impacts thereon of
the COVID-19 pandemic, war in Ukraine and global geopolitical
tension; Immunocore’s ability to obtain, maintain and enforce
intellectual property protection for KIMMTRAK or any product
candidates it is developing; and the success of Immunocore’s
current and future collaborations, partnerships or licensing
arrangements. These and other risks and uncertainties are described
in greater detail in the section titled "Risk Factors" in
Immunocore’s filings with the Securities and Exchange Commission,
including Immunocore’s most recent Annual Report on Form 20-F for
the year ended December 31, 2022 filed with the Securities and
Exchange Commission on March 1, 2023, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and the Company undertakes no duty to update this
information, except as required by law.
CONTACT: ImmunocoreSébastien
Desprez, Head of CommunicationsT: +44 (0)
7458030732E: mailto:sebastien.desprez@immunocore.com Follow
on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor RelationsT: +1 215-384-4781E:
ir@immunocore.com
Unaudited
Condensed Consolidated
Statements of Loss
Comparison of the
Three Months Ended June
30, 2023
and 2022
|
Three Months Ended June
30, |
|
2023 |
|
2022 |
|
$’000 |
|
£’000 |
|
£’000 |
Product revenue, net |
|
57,844 |
|
|
45,514 |
|
|
23,992 |
Pre-product revenue, net |
|
— |
|
|
— |
|
|
3,708 |
Total revenue from sale of therapies |
|
57,844 |
|
|
45,514 |
|
|
27,700 |
Collaboration revenue |
|
2,860 |
|
|
2,250 |
|
|
4,302 |
Total revenue |
|
60,704 |
|
|
47,764 |
|
|
32,002 |
|
|
|
|
|
|
|
|
|
Cost of product revenue |
|
(1,126) |
|
|
(886) |
|
|
(34) |
Research and development expenses |
|
(36,560) |
|
|
(28,767) |
|
|
(20,150) |
Selling and administrative expenses |
|
(43,064) |
|
|
(33,884) |
|
|
(18,811) |
Operating loss |
|
(20,046) |
|
|
(15,773) |
|
|
(6,993) |
Finance income |
|
4,336 |
|
|
3,412 |
|
|
118 |
Finance costs |
|
(1,989) |
|
|
(1,565) |
|
|
(1,397) |
Net finance income / (costs) |
|
2,347 |
|
|
1,847 |
|
|
(1,279) |
Loss before taxation |
|
(17,699) |
|
|
(13,926) |
|
|
(8,272) |
Income tax (charge) / credit |
|
(192) |
|
|
(151) |
|
|
2,151 |
Loss for the period |
|
(17,891) |
|
|
(14,077) |
|
|
(6,121) |
Basic and diluted loss per share - $ / £ |
|
(0.37) |
|
|
(0.29) |
|
|
(0.14) |
Comparison of the
Six Months Ended June
30, 2023
and 2022
|
Six Months Ended June
30, |
|
2023 |
|
2022 |
|
$’000 |
|
£’000 |
|
£’000 |
Product revenue, net |
|
111,288 |
|
|
87,566 |
|
|
31,674 |
Pre-product revenue, net |
|
— |
|
|
— |
|
|
6,537 |
Total revenue from sale of therapies |
|
111,288 |
|
|
87,566 |
|
|
38,211 |
Collaboration revenue |
|
6,023 |
|
|
4,739 |
|
|
16,265 |
Total revenue |
|
117,311 |
|
|
92,305 |
|
|
54,476 |
|
|
|
|
|
|
|
|
|
Cost of product revenue |
|
(1,352) |
|
|
(1,064) |
|
|
(282) |
Research and development expenses |
|
(72,716) |
|
|
(57,216) |
|
|
(38,731) |
Selling and administrative expenses |
|
(85,386) |
|
|
(67,185) |
|
|
(38,916) |
Operating loss |
|
(42,143) |
|
|
(33,160) |
|
|
(23,453) |
Finance income |
|
7,572 |
|
|
5,958 |
|
|
128 |
Finance costs |
|
(4,048) |
|
|
(3,185) |
|
|
(2,730) |
Net finance income / (costs) |
|
3,524 |
|
|
2,773 |
|
|
(2,602) |
Loss before taxation |
|
(38,619) |
|
|
(30,387) |
|
|
(26,055) |
Income tax (charge) / credit |
|
(492) |
|
|
(387) |
|
|
3,806 |
Loss for the period |
|
(39,111) |
|
|
(30,774) |
|
|
(22,249) |
Basic and diluted loss per share - $ / £ |
|
(0.81) |
|
|
(0.64) |
|
|
(0.51) |
Unaudited Condensed
Consolidated Statements of Cash
Flows for Each Period Presented:
|
Six Months Ended June
30, |
|
2023 |
|
2023 |
|
2022 |
|
$’000 |
|
£’000 |
|
£’000 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
|
422,624 |
|
|
332,539 |
|
|
237,886 |
Net cash flows from / (used in) operating activities |
|
8,135 |
|
|
6,401 |
|
|
(40,017) |
Net cash flows from / (used in) investing activities |
|
2,938 |
|
|
2,312 |
|
|
(342) |
Net cash flows from / (used in) financing activities |
|
12,509 |
|
|
9,843 |
|
|
(1,870) |
Net foreign exchange difference on cash held |
|
(11,126) |
|
|
(8,754) |
|
|
12,407 |
Cash and cash equivalents at end of period |
|
435,080 |
|
|
342,341 |
|
|
208,064 |
Unaudited Condensed Consolidated
Statements of Cash Flows for Each Period Presented:
|
Six Months Ended June
30, |
|
2023 |
|
2023 |
|
2022 |
|
$’000 |
|
£’000 |
|
£’000 |
|
|
|
|
|
|
|
|
Cash and cash
equivalents at beginning of period |
|
422,624 |
|
|
332,539 |
|
|
237,886 |
Net cash flows
from / (used in) operating activities |
|
8,135 |
|
|
6,401 |
|
|
(40,017) |
Net cash flows
from / (used in) investing activities |
|
2,938 |
|
|
2,312 |
|
|
(342) |
Net cash flows
from / (used in) financing activities |
|
12,509 |
|
|
9,843 |
|
|
(1,870) |
Net foreign
exchange difference on cash held |
|
(11,126) |
|
|
(8,754) |
|
|
12,407 |
Cash and
cash equivalents at end of period |
|
435,080 |
|
|
342,341 |
|
|
208,064 |
Unaudited Condensed Consolidated
Statements of Financial Position as at
|
|
|
June
30,2023£’000 |
|
December
31,2022£’000 |
Non-current assets |
|
|
|
|
|
|
|
|
Property, plant
and equipment |
|
|
|
|
8,325 |
|
|
6,472 |
Intangible
assets |
|
|
|
|
410 |
|
|
410 |
Right of use
assets |
|
|
|
|
24,233 |
|
|
25,173 |
Other
non-current assets |
|
|
|
|
7,895 |
|
|
7,342 |
Deferred tax
asset |
|
|
|
|
4,442 |
|
|
4,240 |
Total
non-current assets |
|
|
|
|
45,305 |
|
|
43,637 |
Current
assets |
|
|
|
|
|
|
|
|
Inventory |
|
|
|
|
1,891 |
|
|
943 |
Trade and other
receivables |
|
|
|
|
48,458 |
|
|
46,711 |
Tax credits
receivable |
|
|
|
|
2,365 |
|
|
11,688 |
Cash and cash
equivalents |
|
|
|
|
342,341 |
|
|
332,539 |
Total
current assets |
|
|
|
|
395,055 |
|
|
391,881 |
Total
assets |
|
|
|
|
440,360 |
|
|
435,518 |
Equity |
|
|
|
|
|
|
|
|
Share
capital |
|
|
|
|
98 |
|
|
97 |
Share
premium |
|
|
|
|
137,957 |
|
|
123,751 |
Foreign currency
translation reserve |
|
|
|
|
(1,663) |
|
|
(3,097) |
Other
reserves |
|
|
|
|
337,847 |
|
|
337,847 |
Share-based
payment reserve |
|
|
|
|
95,062 |
|
|
81,411 |
Accumulated
deficit |
|
|
|
|
(292,027) |
|
|
(261,253) |
Total
equity |
|
|
|
|
277,274 |
|
|
278,756 |
Non-current liabilities |
|
|
|
|
|
|
|
|
Non-current
accruals |
|
|
|
|
1,646 |
|
|
1,479 |
Interest-bearing
loans and borrowings |
|
|
|
|
37,116 |
|
|
39,500 |
Deferred
revenue |
|
|
|
|
4,331 |
|
|
4,331 |
Lease
liabilities |
|
|
|
|
27,570 |
|
|
28,248 |
Provisions |
|
|
|
|
136 |
|
|
114 |
Total
non-current liabilities |
|
|
|
|
70,799 |
|
|
73,672 |
Current
liabilities |
|
|
|
|
|
|
|
|
Trade and other
payables |
|
|
|
|
85,754 |
|
|
75,076 |
Corporation tax
liability |
|
|
|
|
803 |
|
|
— |
Interest bearing
loans and borrowings |
|
|
|
|
991 |
|
|
— |
Deferred
revenue |
|
|
|
|
3,204 |
|
|
6,408 |
Lease
liabilities |
|
|
|
|
1,513 |
|
|
1,555 |
Provisions |
|
|
|
|
22 |
|
|
51 |
Total
current liabilities |
|
|
|
|
92,287 |
|
|
83,090 |
Total
liabilities |
|
|
|
|
163,086 |
|
|
156,762 |
Total
equity and liabilities |
|
|
|
|
440,360 |
|
|
435,518 |
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024